Biosynex
Market Cap
€76.7m
Last Updated
2020/06/05 23:08 UTC
Data Sources
Company Financials
Executive Summary
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with proven track record.
Similar Companies
Share Price & News
How has Biosynex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALBIO's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-20.8%
ALBIO
-11.5%
FR Medical Equipment
8.7%
FR Market
1 Year Return
197.9%
ALBIO
42.8%
FR Medical Equipment
-2.4%
FR Market
Return vs Industry: ALBIO exceeded the French Medical Equipment industry which returned 47.4% over the past year.
Return vs Market: ALBIO exceeded the French Market which returned -3.8% over the past year.
Shareholder returns
| ALBIO | Industry | Market | |
|---|---|---|---|
| 7 Day | -20.8% | -11.5% | 8.7% |
| 30 Day | -34.4% | -1.9% | 15.9% |
| 90 Day | 84.6% | 35.6% | 1.3% |
| 1 Year | 197.9%197.9% | 42.8%42.8% | -0.7%-2.4% |
| 3 Year | 72.9%72.1% | 43.9%42.1% | 11.2%2.2% |
| 5 Year | 121.3%107.4% | 144.9%139.2% | 31.1%14.3% |
Price Volatility Vs. Market
How volatile is Biosynex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
How Does Biosynex's (EPA:ALBIO) P/E Compare To Its Industry, After The Share Price Drop?3 weeks ago | Simply Wall St
Here's Why Biosynex (EPA:ALBIO) Can Manage Its Debt Responsibly2 months ago | Simply Wall St
Biosynex SA’s (EPA:ALBIO) Investment Returns Are Lagging Its IndustryValuation
Is Biosynex undervalued compared to its fair value and its price relative to the market?
68.78x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALBIO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALBIO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALBIO is poor value based on its PE Ratio (68.8x) compared to the Medical Equipment industry average (47.3x).
PE vs Market: ALBIO is poor value based on its PE Ratio (68.8x) compared to the French market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALBIO is good value based on its PB Ratio (2.5x) compared to the FR Medical Equipment industry average (2.6x).
Next Steps
Future Growth
How is Biosynex forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
11.0%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosynex has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Check out Biosynex's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- Biosynex competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Biosynex performed over the past 5 years?
64.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALBIO has a large one-off loss of €255.3K impacting its December 31 2019 financial results.
Growing Profit Margin: ALBIO's current net profit margins (3.2%) are higher than last year (1.7%).
Past Earnings Growth Analysis
Earnings Trend: ALBIO has become profitable over the past 5 years, growing earnings by 64.5% per year.
Accelerating Growth: ALBIO's earnings growth over the past year (105.5%) exceeds its 5-year average (64.5% per year).
Earnings vs Industry: ALBIO earnings growth over the past year (105.5%) exceeded the Medical Equipment industry -1.8%.
Return on Equity
High ROE: ALBIO's Return on Equity (3.7%) is considered low.
Next Steps
Financial Health
How is Biosynex's financial position?
Financial Position Analysis
Short Term Liabilities: ALBIO's short term assets (€15.1M) exceed its short term liabilities (€8.4M).
Long Term Liabilities: ALBIO's short term assets (€15.1M) exceed its long term liabilities (€8.6M).
Debt to Equity History and Analysis
Debt Level: ALBIO's debt to equity ratio (32.8%) is considered satisfactory.
Reducing Debt: ALBIO's debt to equity ratio has reduced from 47.7% to 32.8% over the past 5 years.
Debt Coverage: Insufficient data to determine if ALBIO's debt is well covered by operating cash flow.
Interest Coverage: ALBIO's interest payments on its debt are well covered by EBIT (7.7x coverage).
Balance Sheet
Next Steps
Dividend
What is Biosynex's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALBIO's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
€96k
CEO Compensation
CEO
Thierry Paper
no data
Tenure
€96,000
Compensation
Dr. Thierry Paper is the Founder of Biosynex S.A. and serves as its Managing Director and Director. Dr. Paper served as Chairman and General Manager of Biosynex S.A.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Biosynex SA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biosynex SA
- Ticker: ALBIO
- Exchange: ENXTPA
- Founded: 1993
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €76.738m
- Shares outstanding: 9.14m
- Website: https://www.biosynex.com
Number of Employees
Location
- Biosynex SA
- 22 Boulevard Sébastien Brant
- Illkirch-Graffenstaden
- Alsace
- 67400
- France
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ALBIO | ENXTPA (Euronext Paris) | Yes | Social Shares | FR | EUR | Mar 2011 |
Biography
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. It offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as instruments. The company also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper-and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/05 23:08 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.